ATE330595T1 - Formulierung von aminosäuren und riboflavin zur verringerung der toxischen effekte der zytotoxischen chemotherapie - Google Patents

Formulierung von aminosäuren und riboflavin zur verringerung der toxischen effekte der zytotoxischen chemotherapie

Info

Publication number
ATE330595T1
ATE330595T1 AT02789801T AT02789801T ATE330595T1 AT E330595 T1 ATE330595 T1 AT E330595T1 AT 02789801 T AT02789801 T AT 02789801T AT 02789801 T AT02789801 T AT 02789801T AT E330595 T1 ATE330595 T1 AT E330595T1
Authority
AT
Austria
Prior art keywords
amino acids
riboflaven
formulation
reduce
pharmaceutical compositions
Prior art date
Application number
AT02789801T
Other languages
German (de)
English (en)
Inventor
Stanislaw R Burzynski
Original Assignee
Stanislaw R Burzynski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanislaw R Burzynski filed Critical Stanislaw R Burzynski
Application granted granted Critical
Publication of ATE330595T1 publication Critical patent/ATE330595T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02789801T 2001-11-27 2002-11-21 Formulierung von aminosäuren und riboflavin zur verringerung der toxischen effekte der zytotoxischen chemotherapie ATE330595T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/995,010 US20030105104A1 (en) 2001-11-27 2001-11-27 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy

Publications (1)

Publication Number Publication Date
ATE330595T1 true ATE330595T1 (de) 2006-07-15

Family

ID=25541300

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02789801T ATE330595T1 (de) 2001-11-27 2002-11-21 Formulierung von aminosäuren und riboflavin zur verringerung der toxischen effekte der zytotoxischen chemotherapie

Country Status (21)

Country Link
US (2) US20030105104A1 (https=)
EP (1) EP1450781B1 (https=)
JP (1) JP4614660B2 (https=)
KR (1) KR100953483B1 (https=)
CN (1) CN100358527C (https=)
AT (1) ATE330595T1 (https=)
BR (1) BR0214430A (https=)
CA (1) CA2468133C (https=)
DE (1) DE60212693T2 (https=)
EA (1) EA009516B1 (https=)
HU (1) HU230986B1 (https=)
IL (2) IL162141A0 (https=)
MX (1) MXPA04004994A (https=)
NO (1) NO332858B1 (https=)
NZ (1) NZ532833A (https=)
PL (1) PL353656A1 (https=)
RO (1) RO121173B1 (https=)
SI (1) SI21542A (https=)
UA (1) UA78977C2 (https=)
WO (1) WO2003045372A1 (https=)
ZA (1) ZA200404115B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013142A1 (en) * 2002-08-02 2004-02-12 The Institute Of Radiation Medicine, Academy Of Miilitary Medical Sciences, People's Liberation Army A riboflavin derivative and its manufacture and uses
US20060035981A1 (en) * 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
US20070248693A1 (en) * 2003-08-02 2007-10-25 Elizabeth Mazzio Nutraceutical composition and method of use for treatment / prevention of cancer
RU2240788C1 (ru) * 2003-09-09 2004-11-27 Воронежская государственная медицинская академия им. Н.Н. Бурденко Детоксикационное средство
SI2153870T1 (sl) 2004-11-26 2014-05-30 Ucl Business Plc Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije
EP2328007B1 (en) * 2005-09-19 2014-12-24 CDM Optics, Inc. Task-based imaging systems
WO2007119378A1 (ja) * 2006-03-15 2007-10-25 Suntory Limited リボフラビンとセサミン類とを含有する組成物
WO2008050836A1 (en) * 2006-10-25 2008-05-02 Ajinomoto Co., Inc. Agent for ameliorating adverse side-effect of chemotherapeutic agent
JPWO2008105384A1 (ja) * 2007-02-26 2010-06-03 協和発酵バイオ株式会社 シトルリン含有錠剤
AU2008239318B2 (en) 2007-03-15 2013-10-03 Suntory Holdings Limited Anti-fatigue agent
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
AU2014200578B2 (en) * 2008-09-19 2016-08-11 Société des Produits Nestlé S.A. Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment
RU2011115184A (ru) 2008-09-19 2012-10-27 Нестек С.А. (Ch) Питательная поддержка для предупреждения или ослабления паралича костного мозга или нейтропении во время противораковой терапии
HUE035921T2 (en) 2009-04-03 2018-05-28 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
CN104434894A (zh) 2009-06-08 2015-03-25 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
US8449512B2 (en) 2010-04-09 2013-05-28 Davinci Biomedical Research Products Inc. Stoma stabilitating device and method
EP2397458A1 (en) * 2010-06-21 2011-12-21 Lunamed AG Organic salts and co-crystals of phenylbutyric acid
JP2013532661A (ja) 2010-07-22 2013-08-19 リベン ファーマシューティカルズ インコーポレイテッド 磁気双極子安定化溶液の使用を含む疾患を処置または改善する方法および行動を向上させる方法
MX350541B (es) * 2010-09-24 2017-09-08 Univ Florida Materiales y metodos para mejorar la funcion gastrointestinal.
US8946473B2 (en) 2010-10-06 2015-02-03 Ocera Therapeutics, Inc. Methods of making L-ornithine phenyl acetate
CN103429234B (zh) 2010-12-10 2016-10-05 布罗迪健康科学有限公司 茉莉酮酸酯治疗膀胱功能障碍的用途
KR101919747B1 (ko) * 2011-02-17 2018-11-20 각꼬호우진 구루메 다이가쿠 화학요법제의 항종양 활성 증강제
PL2729008T3 (pl) * 2011-07-07 2017-10-31 Res Cancer Institute Of America Systemy, sposoby i formulacje do leczenia raka
EP2968241B1 (en) 2013-03-11 2018-10-31 University of Florida Research Foundation, Inc. Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications
WO2015067759A1 (en) * 2013-11-08 2015-05-14 Legacy Healthcare Ltd Method for the management of cancer and treatment of cancer comorbidities
JP6598425B2 (ja) * 2014-02-27 2019-10-30 花王株式会社 疲労の評価方法
ES2769000T3 (es) 2014-11-24 2020-06-24 Ucl Business Ltd Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco
WO2017031131A1 (en) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
CN105495582A (zh) * 2015-12-11 2016-04-20 北京康比特体育科技股份有限公司 一款抗疲劳、促恢复的保健食品氨基酸组合物
MX389665B (es) 2017-05-11 2025-03-20 Ocera Therapeutics Inc Procesos para producir fenilacetato de l-ornitina

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535049A (en) * 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
JPS58126767A (ja) * 1982-01-22 1983-07-28 Ajinomoto Co Inc 肝臓病患者用栄養組成物
ATE54826T1 (de) * 1985-10-23 1990-08-15 Mulli Kurt Nachf Gmbh Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
US5045468A (en) * 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
ES2063882T5 (es) * 1989-10-02 2001-12-01 Novartis Nutrition Ag Hidrolizados de proteinas.
US5292773A (en) * 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
DE69331528T2 (de) * 1992-12-23 2002-10-31 Abbott Laboratories, Abbott Park Medizinische nahrungsmittel für die ernährungsergänzung bei metabolischen erkrankungen von säuglingen/kleinkindern
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
FR2705765B1 (fr) * 1993-04-29 1995-08-18 Eurofours Sa Porte de four.
US5547927A (en) * 1993-05-28 1996-08-20 Abbott Laboratories Enteral nutritional product for patients undergoing radiation therapy and/or chemotherapy
NZ248605A (en) * 1993-05-28 1994-12-22 Abbott Lab Enteral nutritional product comprising protein and fat
US5719133A (en) * 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition
US5656608B1 (en) * 1995-02-23 2000-09-26 Novartis Nutrition Ltd Amino acid compositions and methods of treatment using same
US5728678A (en) * 1995-06-06 1998-03-17 Nestec Ltd. Method and composition for providing nutrition to a renal failure patient
US5776913A (en) * 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma
ATE310505T1 (de) * 1996-05-14 2005-12-15 Stanislaw R Burzynski Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität
US5817927A (en) * 1997-04-11 1998-10-06 Betzdearborn Inc. Method and apparatus for monitoring water process equipment
US5817695A (en) * 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
PT1062879E (pt) 1999-06-26 2003-12-31 Braun Melsungen Ag Solucao aquosa para nutricao parenteral
GB0009056D0 (en) * 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
US6377094B1 (en) * 2002-03-25 2002-04-23 Oak Technology, Inc. Arbitrary waveform synthesizer using a free-running ring oscillator

Also Published As

Publication number Publication date
US7427619B2 (en) 2008-09-23
EA200400737A1 (ru) 2004-12-30
JP2005518361A (ja) 2005-06-23
CA2468133A1 (en) 2003-06-05
HUP0402240A2 (hu) 2005-02-28
WO2003045372A1 (en) 2003-06-05
ZA200404115B (en) 2005-11-30
IL162141A0 (en) 2005-11-20
AU2002352843A1 (en) 2003-06-10
KR20040065565A (ko) 2004-07-22
NO332858B1 (no) 2013-01-21
EP1450781A1 (en) 2004-09-01
US20050182064A1 (en) 2005-08-18
RO121173B1 (ro) 2007-01-30
DE60212693D1 (de) 2006-08-03
HU230986B1 (hu) 2019-08-28
CN1596109A (zh) 2005-03-16
JP4614660B2 (ja) 2011-01-19
SI21542A (sl) 2005-02-28
EA009516B1 (ru) 2008-02-28
DE60212693T2 (de) 2007-07-05
CA2468133C (en) 2011-02-22
EP1450781B1 (en) 2006-06-21
MXPA04004994A (es) 2005-04-08
CN100358527C (zh) 2008-01-02
KR100953483B1 (ko) 2010-04-16
NO20042364L (no) 2004-06-07
US20030105104A1 (en) 2003-06-05
BR0214430A (pt) 2004-11-03
NZ532833A (en) 2006-12-22
PL353656A1 (en) 2003-06-02
UA78977C2 (en) 2007-05-10
IL162141A (en) 2009-05-04
HUP0402240A3 (en) 2012-09-28

Similar Documents

Publication Publication Date Title
ATE330595T1 (de) Formulierung von aminosäuren und riboflavin zur verringerung der toxischen effekte der zytotoxischen chemotherapie
PL365783A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
EA200600877A1 (ru) Наночастицы для доставки лекарств
BR0305628A (pt) Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
DE60228857D1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
NO991836L (no) Antranilinsyrederivater som modulatorer av multimedikamentresistens
MXPA02012164A (es) Derivados de tiofeno activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden.
AU2003218989A1 (en) Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
NO911854D0 (no) Fremgangsmaate for fremstilling av peptid-derivater.
TNSN05180A1 (en) Liquid pharmaceutical formulations of palonosetron
SE0102036D0 (sv) Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
YU64602A (sh) Smeša koja se sastoji od kamptotecina i derivata pirimidina za terapiju kancera
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
ATE521624T1 (de) Peptide und medizinische zusammensetzungen mit denselben
WO2003068157A3 (en) Kinase inhibitors and methods of use thereof
ATE349221T1 (de) Extrakt mit antitumoraler und antitoxischer wirkung
EP1482933A4 (en) EFFECTIVE SIMPLIFIED DERIVATIVES OF IMMUNOSUPPRESSIVA
BRPI0507811A (pt) derivados de 7h-pirrolopirimidina
ITMI20021040A1 (it) Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
WO2004073627A3 (en) Novel therapeutic method and compositions for topical administration

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties